Group A: omega‐3 fatty acids may leads to lower prodromal symptoms: transition to psychosis Long‐term (events) compared with placebo (low certainty).
It is very uncertain whether group C other: family treatment changes adverse events: suicide (events) Long‐term (by 24 months) compared with enhanced care (very low certainty).
It is very uncertain whether group C other: family treatment changes satisfaction with treatment: leaving the study early FACT Long‐term compared with enhanced care (very low certainty).
It is very uncertain whether group C other: integrated treatment changes prodromal symptoms: transition to psychosis Endpoint data (events)… compared with standard treatment (very low certainty).
Group A: omega‐3 fatty acids may leads to lower global state: antipsychotic prescription Long‐term (events) compared with placebo (low certainty).
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in global state: 1a. Relapse ‐ long term compared with STANDARD CARE ALONE (low certainty).
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes global state: 2. Clinically important change (no improvement) ‐ long… compared with STANDARD CARE ALONE (very low certainty).
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes mental state: General ‐ clinically important change (no improvement)… compared with STANDARD CARE ALONE (very low certainty).
COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in satisfaction with treatment: 1. Leaving the study early ‐ long term compared with STANDARD CARE ALONE (moderate certainty).
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
The review found no eligible studies for this question.
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with non‐Intensive Case Management (low certainty).
The review found no eligible studies for this question.
Intensive Case Management showed no clear difference in adverse event: 1b. Death ‐ suicide ‐ by long term compared with standard care (low certainty).